All News

Investigators of the phase 3 KEYNOTE-671 trial identify no new safety signals with pembrolizumab plus chemotherapy in those with early-stage non–small cell lung cancer.

Collaboration among surgical specialties allows for safe removal of all visible tumors, thus improving survival in patients with advanced ovarian cancer, says Donal J. Brennan, MB, PhD.

Results from a phase 1 of study of 177Lu-PSMA-617 in combination with pembrolizumab show significant anti-tumor activity with low toxicity in patients with metastatic castration-resistant prostate cancer.

Results from the phase 3 KEYNOTE-966 trial led to the approval of pembrolizumab plus gemcitabine and cisplatin for patients with locally advanced unresectable or metastatic biliary tract cancer.

With the announcement that the supply of 177Lu vipivotidete traxetanis now unconstrained, the targeted radioligand will be available in over 200 centers for patients with prostate cancer. 

The FDA has set a Prescription Drug User Fee Act date of April 30, 2024 for tovorafenib as a treatment for pediatric patients with relapsed or progressive low-grade glioma.

Mirvetuximab soravtansine-gynx may have the potential to become a new standard for patients with folate receptor α–positive, platinum-resistant ovarian cancer, experts say.

Novel anti-PSMA monoclonal antibody rosopatamab is capable of carrying a bigger payload of radiation particles, which may potentially reduce doses for patients with prostate cancer, says Neeraj Agarwal, MD.

Patients with breast cancer harboring BRCA1/2 mutations appear to be more likely to undergo mastectomies than those without, according to Zachary Kiss, DO.

Rebecca M. Shulman, MD, and Zachary Kiss, DO, discuss findings from a study evaluating differences in outcomes with radiotherapy and disease characteristics of patients with breast cancer harboring BRCA mutations compared with those without mutated disease.

Data from the phase 3 MIRASOL trial support the European marketing authorization application for mirvetuximab soravtansine as a treatment for folate receptor α–positive, platinum-resistant ovarian cancer.

The regulatory agency has set a Prescription Drug User Fee Act date of April 23, 2024 for N-803 plus BCG as a treatment for BCG-unresponsive, non–muscle invasive bladder carcinoma.

Study shows a high prevalence of thyroid cancer in transgender female patients.

Data from the phase 3 RATIONALE-301 trial appear to support tislelizumab as a potential frontline treatment option for patients with unresectable hepatocellular carcinoma.

Data from the phase 3 JUPITER-02 study and phase 2 POLARIS-02 study support the FDA approval of toripalimab-tpzi alone and in combination with gemcitabine and cisplatin in nasopharyngeal carcinoma.

Paige Lymph Node is the first artificial intelligence application of its kind to receive breakthrough device designation from the FDA for detecting breast cancer metastases.

Investigators will assess the safety and preliminary anti-tumor activity of ONCT-534 in metastatic castration-resistant prostate cancer in the phase 1/2 study ONCT-534-101.

Findings from a phase 2 trial also show that there is no progression-free survival or overall survival benefit with lapatinib plus chemoradiotherapy in patients with non-human papillomavirus–related head and neck cancer.

Dose adjustments and alternative treatment regimens may be required amid hematologic drug shortages.

Data from the phase 3 RUBY/ENGOT-EN6/GOG3031/NSGO trial support the use of frontline dostarlimab plus chemotherapy for dMMR/MSI-H primary advanced or recurrent endometrial cancer.

Data from the phase 3 KEYNOTE-091 trial supported the European Commission’s approval of pembrolizumab as an adjuvant treatment for adults with non–small cell lung cancer at high risk of recurrence following complete resection and platinum-based chemotherapy.

CB-012 is set to be investigated as part of the phase 1 AMpLify trial in patients with relapsed/refractory acute myeloid leukemia.

The Canadian approval of relugolix for advanced prostate cancer is based on findings from the phase 3 HERO study.

A phase 1 study will evaluate TERN-701’s safety, efficacy, and pharmacokinetics in a population diagnosed with chronic myeloid leukemia.

Findings from recent studies support the use of artificial intelligence-based tools in the context of radiation therapy for patients with localized prostate cancer, according to Neeraj Agarwal, MD.

Ivosidenib monotherapy is now approved by the FDA for patients with relapsed/refractory myelodysplastic syndrome with an IDH1 mutation.

The primary end point of overall response rate is met in the phase 2 ROSEWOOD study of patients with relapsed/refractory follicular lymphoma receiving zanubrutinib plus obinutuzumab vs obinutuzumab monotherapy.

Efficacy and safety data from the phase 2b SUNRISE-1 trial support the ongoing evaluations of TAR-200 as a treatment for patients with BCG-unresponsive high-risk non–muscle-invasive bladder cancer.

Data from a phase 2 trial suggests that earlier use of abiraterone acetate/prednisone plus cabazitaxel may elicit clinical benefit in patients with metastatic castration-resistant prostate cancer.

Amivantamab plus chemotherapy may be the new standard of care for patients with EGFR-mutated advanced non–small cell lung cancer that has progressed following osimertinib, according to Antonio Passaro, MD, PhD.